AWM
CNTX icon

Aspire Wealth Management’s Context Therapeutics CNTX Stock Holding History

Aspire Wealth Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$11.3K – 190
2023
Q4 		$11.3K Hold
10,000
– – 0.01% 154
2023
Q3 		$15.1K Hold
10,000
– – 0.01% 147
2023
Q2 		$16K Hold
10,000
– – 0.01% 153
2023
Q1 		$5.62K Hold
10,000
– – ﹤0.01% 167
2022
Q4 		$6.52K Buy
+10,000
New +$10.8K 0.01% 162

Other funds holding CNTX

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aspire Wealth Management's CNTX Position: Q1 2024 in Review

Aspire Wealth Management sold out of Context Therapeutics (CNTX) in Q1 2024, closing a stake of 10,000 shares — an estimated $11.3K sold.

Aspire Wealth Management first reported a position in CNTX in Q4 2022 and held it in 5 quarters. The position peaked at $16K in Q2 2023. 25 funds tracked by Wall St. Rank hold CNTX as of Q1 2024.

  • Aspire Wealth Management reported no remaining Context Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Aspire Wealth Management sold 10,000 Context Therapeutics shares in Q1 2024, an estimated $11.3K.
  • Aspire Wealth Management first reported a position in Context Therapeutics in Q4 2022 and held it in 5 quarters.
  • Aspire Wealth Management's Context Therapeutics position peaked at $16K in Q2 2023.
  • 25 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2024.

Based on Aspire Wealth Management's 13F filing for Q1 2024, filed 29 Apr 2024.